Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/135362
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGreenhouse, Bryan-
dc.contributor.authorDaily, Jennifer-
dc.contributor.authorGuinovart, Caterina-
dc.contributor.authorGoncalves, Bronner-
dc.contributor.authorBeeson, James G.-
dc.contributor.authorBell, David-
dc.contributor.authorChang, Michelle A.-
dc.contributor.authorCohen, Justin M.-
dc.contributor.authorDing, Xavier C.-
dc.contributor.authorDomingo, Gonzalo-
dc.contributor.authorEisele, Thomas P.-
dc.contributor.authorLammie, Patrick J.-
dc.contributor.authorMayor Aparicio, Alfredo Gabriel-
dc.contributor.authorMerienne, Nicolas-
dc.contributor.authorMonteiro, Wuelton Marcelo-
dc.contributor.authorPainter, John-
dc.contributor.authorRodríguez, Isabel-
dc.contributor.authorWhite, Michael T.-
dc.contributor.authorDrakeley, Chris-
dc.contributor.authorMueller, Ivo-
dc.contributor.authorMalaria Serology Convening-
dc.date.accessioned2019-06-18T15:29:47Z-
dc.date.available2019-06-18T15:29:47Z-
dc.date.issued2019-06-07-
dc.identifier.issn2572-4754-
dc.identifier.urihttp://hdl.handle.net/2445/135362-
dc.description.abstractMeasurement of malaria specific antibody responses represents a practical and informative method for malaria control programs to assess recent exposure to infection. Technical advances in recombinant antigen production, serological screening platforms, and analytical methods have enabled the identification of several target antigens for laboratory based and point-of-contact tests. Questions remain as to how these serological assays can best be integrated into malaria surveillance activities to inform programmatic decision-making. This report synthesizes discussions from a convening at Institut Pasteur in Paris in June 2017 aimed at defining practical and informative use cases for serology applications and highlights five programmatic uses for serological assays including: documenting the absence of transmission; stratification of transmission; measuring the effect of interventions; informing a decentralized immediate response; and testing and treating P. vivax hypnozoite carriers.-
dc.format.extent16 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBill and Melinda Gates Foundation-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.12688/gatesopenres.12897.1-
dc.relation.ispartofGates Open Research, 2019, vol. 3 , num. 131-
dc.relation.urihttp://dx.doi.org/10.12688/gatesopenres.12897.1-
dc.rightscc by (c) Greenhouse et al., 2019-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (ISGlobal)-
dc.subject.classificationMalària-
dc.subject.classificationSerodiagnòstic-
dc.subject.otherMalaria-
dc.subject.otherSerodiagnosis-
dc.titlePriority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2019-06-14T09:57:39Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
GreenhouseB_Gates_Open_Res_2019.pdf311.88 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons